TMCnet News
ExCellThera announces clinical trial results using ECT-001 to be presented at ASH 2018 annual meetingMONTREAL, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced that results from the Phase I/II clinical trial using its lead technology, ECT-001, for allogeneic stem cell transplant, will be presented at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego. Details of the presentation are as follows: Date & Time: Monday, December 3, 2018; 6:00-8:00 p.m. PT Title: Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent GvHD Relapse Free Survival Abstract Number: 4658 Lead Author: Sandra Cohen, MD, FRCP(C), Division of Hematology and Medical Oncology, Stem Cell Transplant Program, Departent of Medicine, University of Montreal and Maisonneuve-Rosemont Hospital, Montreal, QC, Canada Location: San Diego Convention Center, Hall GH About ECT-001 About ExCellThera Inc.
Contacts: Investor Inquiries David Millette Chief Financial and Legal Officer [email protected] Media Inquiries Lisa Willemse Chief Marketing Officer [email protected] |